Molindone
General information:
| Withdrawn ID: | 408 |
|---|---|
| Canonical SMILES: | |
| Standard InChI: | |
| Standard InChIKey: | |
| ATC class(es): | N05AE02 |
| Molecular Formula: | C16H24N2O2 |
| Molweight: | 276.374 |
Withdrawal information:
| Withdrawn due to drug safety reasons: | No |
|---|---|
| First approved: | 1974 |
Side-effects:
| Total reported cases (submitted by medical professionals) with Molindone as primary suspect: | 3 |
|---|
Reported final outcomes:
| Disability: | 1 |
|---|---|
| Intervention required to prevent permanent impairment/damage: | 1 |
| Hospitalization (initial or prolonged): | 1 |
Reported side-effects:
| Side-effect | Case number |
|---|---|
| PYREXIA | 1 |
| NYSTAGMUS | 1 |
| MUSCULOSKELETAL STIFFNESS | 1 |
| Hypersensitivity | 1 |
| DYSTONIA | 1 |
Filtered ChEMBL targets:
| Target UniProtKB ID | Activity in nm | Target Name | Target gene |
|---|---|---|---|
| P34969 | 265 | 5-hydroxytryptamine receptor 7 | 5HT7R_HUMAN |
Toxicity information:
| Toxicity class: | 3 |
|---|---|
| Toxicity type: | N/A |
| LD50: | 220 mg/kg |
External links:
| ChEBML: | CHEMBL460 |
|---|---|
| DrugBank: | DB01618 |